SGLT2 inhibitor dapagliflozin attenuates pro-oxidative cardiomyocyte injury induced by PI3K selective inhibitor alpelisib and fulvestrant under hyperglycemia

20 June 2026 (13:15 - 14:15)
Organised by: Logo
Congress Presentation Part of: Research in cancer therapy-related cardiovascular toxicity: from bench to bedside Cardio-Oncology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology